Maureen Cooper

Maureen Cooper has a degree in Bioinformatics from the City University of New York and has spent over 15 years in the molecular diagnostics space. Her experience includes academic research at the University of Pittsburgh as well as industry where she has held multiple Commercial and Medical Affairs roles. Over the course of her career, Maureen has focused on educating Oncologists and Pathologists on the value of biomarker testing for cancer patients and building testing pathways for Oncology programs through education and collaboration.

Labcorp unveils new name for future independent clinical development business: Fortrea

Fortrea Will Become a Leading, Pure-play CRO Focused on Driving Innovation and Improving Patient Outcomes Worldwide Spin-off Remains on Track to Be Completed in Mid-2023 BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 9, 2023-- Labcorp (NYSE: LH), a leading global life sciences company, today announced

The clinical relevance of anti-DFS70 autoantibodies

 

Presentation on the use of the anti-DFS70 antibodies to help identify ANA-positive individuals who do not have an ANA-associated autoimmune disease (AARD), especially in the absence of significant clinical findings.

Speaker

Vincent Ricchiuti, PhD Laboratory Director and Discipline Director in Immunology, Labcorp

Cases in biologic and other specialized therapeutic drug monitoring

 

Presentation on the use of traditional and biologic therapeutic drug monitoring to help physicians optimize the management of rheumatic disorders.

Speaker

Jane Yang, MD, Medical Science Director, Labcorp

Seronegative rheumatoid arthritis: Biomarkers for diagnosis webinar

 

Presentation on the use of novel rheumatoid arthritis (RA) markers that may help recognize RA as early as possible.

Speaker

Stanley J. Naides, MD, FACP, FACR Medical Science Liaison, Medical Affairs